Case Study | Beat AML® Master Trial

 Learn how Syneos Health provides full-service clinical services to help expedite the development of innovative therapies for acute myeloid leukemia patients.

The Beat AML® Master Trial, initiated by the Leukemia & Lymphoma Society in collaboration with the FDA, leading leukemia doctors, and biopharmaceutical companies, aims to expedite the development of targeted therapies for newly diagnosed acute myeloid leukemia (AML) patients using next-generation sequencing. Syneos Health is providing full-service clinical development support to this innovative "umbrella" trial, which seeks to streamline data processes and improve efficiency, thereby accelerating drug registration.

Fill out the form below to download the content.